ATAGI 2022 Annual Statement on Immunisation

Authors

  • Australian Technical Advisory Group on Immunisation Immunisation Branch, Australian Government Department of Health and Aged Care, GPO Box 9848 – MDP 13, Canberra ACT 2601
  • Catherine T Tran National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia
  • Madeline Valeri National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia
  • Clayton Chiu Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Michelle L Giles Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia; Department of Infectious Diseases, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
  • Allen C Cheng Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
  • Kristine K Macartney National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia
  • Christopher C Blyth Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Wesfarmers Centre of Vaccines and Infecetious Diseases, Telethon Kids Institute and School of Medicine, University of Western Australia, Perth, Western Australia, Australia; Department of Infectious Diseases, Perth Children’s Hospital and PathWest Laboratory Medicine, QEII Medical Centre, Perth, Western Australia, Australia
  • Nigel W Crawford Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Department of General Paediatrics,yal Children’s Hospital, Melbourne, Victoria, Australia; Infection and Immunity, Murdoch Children’s Research Institute and University of Melbourne, Victoria, Australia

DOI:

https://doi.org/10.33321/cdi.2022.46.67

Keywords:

immunisation, vaccines, COVID 19, Australia

Abstract

In 2021, immunisation issues in Australia were dominated by the coronavirus disease 2019 (COVID-19) vaccine roll-out. COVID-19 control measures continued to contribute to lower rates of many vaccine-preventable diseases (VPDs) in Australia.

Downloads

Download data is not yet available.

References

Australian Government Department of Health and Aged Care. ATAGI clinical guidance for COVID-19 vaccine providers. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2022. Available from: https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance.

Australian Government Department of Health and Aged Care. Resources for COVID-19 vaccine providers. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 19 November 2021. Available from: https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/resources.

Australian Government Department of Health and Aged Care. COVID-19 vaccination – Patient resources. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2022. Available from: https://www.health.gov.au/resources/collections/covid-19-vaccination-patient-resources.

Australian Government Department of Health and Aged Care. COVID-19 vaccination information for Aboriginal and Torres Strait Islander people. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2022. Available from: https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/indigenous.

Australian Government Department of Health and Aged Care. Australian Technical Advisory Group on Immunisation (ATAGI). [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2022. Available from: https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi.

Australian Government Department of Health and Aged Care. COVID-19 vaccination – Australian COVID-19 Vaccination Policy. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 13 November 2020. Available from: https://www.health.gov.au/resources/publications/covid-19-vaccination-australian-covid-19-vaccination-policy.

Australian Government Department of Health and Aged Care. COVID-19 vaccination – Australia’s COVID-19 vaccine national roll-out strategy. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 7 January 2021. Available from: https://www.health.gov.au/resources/publications/covid-19-vaccination-australias-covid-19-vaccine-national-roll-out-strategy.

Australian Government Department of Health and Aged Care. ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 8 April 2021. Available from: https://www.health.gov.au/news/atagi-statement-on-astrazeneca-vaccine-in-response-to-new-vaccine-safety-concerns.

Australian Government Department of Health and Aged Care. ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 17 June 2021. Available from: https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021.

Australian Government Department of Health and Aged Care. ATAGI statement on the use of COVID-19 vaccines in all young adolescents in Australia. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 27 August 2021. Available from: https://www.health.gov.au/news/atagi-statement-on-the-use-of-covid-19-vaccines-in-all-young-adolescents-in-australia.

Australian Government Department of Health and Aged Care. ATAGI statement on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 25 March 2022. Available from: https://www.health.gov.au/news/atagi-statement-on-the-use-of-a-3rd-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised.

Australian Government Department of Health and Aged Care. ATAGI recommendations on the use of a booster dose of COVID-19 vaccine. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 25 March 2022. Available from: https://www.health.gov.au/resources/publications/atagi-recommendations-on-the-use-of-a-booster-dose-of-covid-19-vaccine.

Australian Government Department of Health and Aged Care. ATAGI recommendations on Pfizer COVID-19 vaccine use in children aged 5 to 11 years. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 9 December 2021. Available from: https://www.health.gov.au/resources/publications/atagi-recommendations-on-pfizer-covid-19-vaccine-use-in-children-aged-5-to-11-years.

Australian Government Department of Health and Aged Care Therapeutic Goods Adminsitration (TGA). COVID-19 vaccine approval process. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 6 July 2021. Available from: https://www.tga.gov.au/covid-19-vaccine-approval-process.

Australian Government Department of Health and Aged Care. National Immunisation Program (NIP) vaccine listing process. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 18 December 2017. Available from: https://www.health.gov.au/resources/publications/national-immunisation-program-nip-vaccine-listing-process.

TGA. International COVID-19 vaccines recognised by Australia. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 16 May 2022. Available from: https://www.tga.gov.au/international-covid-19-vaccines-recognised-australia.

TGA. Australia’s COVID-19 vaccine safety monitoring system. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 9 February 2021. Available from: https://www.tga.gov.au/australias-covid-19-vaccine-safety-monitoring-system.

TGA. COVID-19 vaccine safety monitoring plan. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 9 February 2021. Available from: https://www.tga.gov.au/resource/covid-19-vaccine-safety-monitoring-plan.

TGA. COVID-19 vaccine safety report. [Website.] Canberra: Australian Government Department of Health and Aged Care, TGA; 2021. Available from: https://www.tga.gov.au/news/covid-19-vaccine-safety-reports.

Australian Government Department of Health and Aged Care. Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2022. Available from: https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi-covid-19-working-group.

AusVaxSafety. COVID-19 vaccines. [Internet.] Sydney: National Centre for Immunisation Research and Surveillance (NCIRS). Available from: https://ausvaxsafety.org.au/safety-data/covid-19-vaccines.

Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ). COVID-19 related resources. [Internet.] Melbourne: THANZ; 2022. Available from: https://www.thanz.org.au/resources/covid-19.

Australian Government Department of Health and Aged Care. COVID-19 vaccination – Guidance on Myocarditis and Pericarditis after mRNA COVID-19 vaccines. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 30 July 2021. Available from: https://www.health.gov.au/resources/publications/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-mrna-covid-19-vaccines.

Australian Government Department of Health and Aged Care. Australian Influenza Surveillance Report and Activity Updates – 2021. [Internet.] Canberra: Australian Government, Department of Health and Aged Care; 2021. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-ozflu-2021.htm.

Swift C, Dey A, Jayasinghe S, Brotherton J, Rashid H, Clark K et al. Impact evaluation of Australian national human papillomavirus vaccination program. Sydney: NCIRS; February 2021. Available from: https://www.ncirs.org.au/sites/default/files/2021-11/Impact%20evaluation%20of%20national%20HPV%20vaccination%20program_February%202021%20Report_0.pdf.

National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Cervical Cancer Control. Cervical Cancer Elimination Progress Report: Australia’s progress towards the elimination of cervical cancer as a public health problem. Melbourne: NHMRC; 26 March 2021. Available from: https://www.cervicalcancercontrol.org.au/wp-content/uploads/2021/03/2021-C4-CRE-Elim-Report.pdf.

HPV vaccine. HPV resources for health professionals. [Internet.] Melbourne: Cancer Council Victoria. Available from: https://www.hpvvaccine.org.au/health-professionals/health-professionals-resources.aspx.

Whop LJ, Butler TL, Brotherton JML, Anderson K, Cunningham J, Tong A et al. Study protocol: Yarning about HPV Vaccination: a qualitative study of factors influencing HPV vaccination among Aboriginal and Torres Strait Islander adolescents in Australia. BMJ Open. 2021;11(8):e047890. doi: https://doi.org/10.1136/bmjopen-2020-04789.

Lowitja Institute. Investigating cross-cultural responses to the introduction of the HPV vaccine. [Internet.] Melbourne: Australian Government Department of Industry, Innovation and Science, Lowitja Institute; 2008. Available from: https://www.lowitja.org.au/page/research/research-categories/science-and-health-conditions/health-conditions/completed-projects/cross-cultural-responses-hpv.

McMillan M, Wang B, Koehler AP, Sullivan TR, Marshall HS. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73(1):e233–7. doi: https://doi.org/10.1093/cid/ciaa1636.

Australian Government Department of Health and Aged Care. National Immunisation Program: Shingles vaccination catch-up program extended. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 15 October 2021. Available from: https://www.health.gov.au/news/national-immunisation-program-shingles-vaccination-catch-up-program-extended.

Australian Government Department of Health and Aged Care. ATAGI advice on seasonal influenza vaccines in 2021 – December 2021 update. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 7 December 2021. Available from: https://www.health.gov.au/resources/publications/atagi-advice-on-seasonal-influenza-vaccines-in-2021-december-2021-update.

Australian Government Department of Health and Aged Care. Australian Immunisation Handbook. [Website.] Canberra: Australian Government Department of Health and Aged Care, ATAGI. Available from: https://immunisationhandbook.health.gov.au/.

Australian Government Department of Health and Aged Care. Statement on the clinical use of zoster vaccine in older adults in Australia. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 5 July 2021. Available from: https://www.health.gov.au/resources/publications/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia.

Australian Government. Australian Immunisation Register Amendment (Reporting) Act 2021. [Legislation.] Canberra: Australian Government Federal Register of Legislation; 15 February 2021. Available from: https://www.legislation.gov.au/Details/C2021A00001.

AusVaxSafety. AusVax Safety. [Website.] Sydney: NCIRS. Available from: https://ausvaxsafety.org.au/.

TGA. Safety advisory - careful assessment and screening for immunocompromise essential before administration of Zostavax. Regulatory context and recommended resources. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 17 February 2022. Available from: https://www.tga.gov.au/alert/zostavax#:~:text=The%20TGA%20has%20published%20safety,of%20registration%20imposed%20in%20by.

Australasian Society of Clinical Immunology and Allergy (ASCIA). Information updates. Safety Alert: Zostavax Vaccine – NOT to be used in people with compromised immune function. [Internet.] Sydney: ASCIA; 23 December 2020. Available from: https://www.allergy.org.au/about-ascia/info-updates/safety-alert-zostavax-vaccine-not-to-be-used-in-people-with-compromised-immune-function.

TGA. Zostavax vaccine. Safety measures to address risk of infection with the vaccine virus. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 2 June 2021. Available from: https://www.tga.gov.au/alert/zostavax-vaccine-2.

Australian Government Department of Health and Aged Care. ATAGI strategic intent. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 10 September 2020. Available from: https://www.health.gov.au/resources/publications/atagi-strategic-intent.

Downloads

Published

20/10/22

How to Cite

Australian Technical Advisory Group on Immunisation, Catherine T Tran, Madeline Valeri, Clayton Chiu, Michelle L Giles, Allen C Cheng, Kristine K Macartney, Christopher C Blyth, and Nigel W Crawford. 2022. “ATAGI 2022 Annual Statement on Immunisation ”. Communicable Diseases Intelligence 46 (October). https://doi.org/10.33321/cdi.2022.46.67.

Issue

Vol. 46 (2022)

Section

Notice to readers

Categories

License

Copyright (c) 2022 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 > >>